ICAR-CIBA Partners with Neomeds for Breakthrough Shrimp Disease Treatment

As part of a significant development for the aquaculture industry, the ICAR-Central Institute of Brackishwater Aquaculture (ICAR-CIBA) based in Chennai has inked a Memorandum of Understanding (MoU) with M/s Neomeds, headquartered in Hyderabad, Telangana.

The collaboration aims to facilitate the technology transfer of 'CIBA EHP Cura I' - an innovative solution addressing Enterocytozoon hepatopenaei (EHP), a microsporidian pathogen posing a serious threat to the global shrimp industry.

Following six to seven years of dedicated research on EHP, ICAR-CIBA successfully developed 'CIBA EHP Cura I,' a groundbreaking treatment that underwent rigorous field validation before being commercialized. Dr. Kuldeep K. Lal, Director of ICAR-CIBA, emphasized the criticality of combating the EHP pathogen in shrimp aquaculture and underscored the importance of 'CIBA EHP Cura I' in mitigating this challenge, particularly for the farming community in India.

Dr. T. Sathish Kumar, Scientist and Principal Investigator of 'CIBA EHP Cura I,' provided insights into the genesis of the product's development and its pivotal role in the treatment and control of EHP. He further elaborated on the partnership with M/s Neomeds, marking a significant step towards expanding the reach and impact of this groundbreaking technology.

The collaboration between ICAR-CIBA and Neomeds heralds a promising era in shrimp disease management, offering hope to farmers grappling with the devastating effects of EHP. With 'CIBA EHP Cura I' poised to make waves in the aquaculture sector, stakeholders anticipate a positive transformation in shrimp farming practices, bolstering sustainability and resilience against disease outbreaks.

(Source: ICAR-Central Institute of Brackishwater Aquaculture, Chennai)